Rezolute (RZLT) Receivables - Notes (2012 - 2013)
Rezolute (RZLT) reported Receivables - Notes of $163829.0 for Q1 2013, down 80.32% sequentially from $832454.0 in Q2 2012.
Rezolute (RZLT) Receivables - Notes (2012 - 2013) Analysis & Trends
Rezolute (RZLT) has 2 years of Receivables - Notes data on file, last reported at $163829.0 in Q1 2013.
- For the quarter ending Q1 2013, Receivables - Notes changed N/A year-over-year to $163829.0; the trailing twelve-month figure through Mar 2013 stood at $163829.0 (changed N/A YoY), and the FY2012 full-year result was $832454.0, changed N/A from the prior year.
- Receivables - Notes retreated to $163829.0 in Q1 2013, from $832454.0 in the prior quarter.
- In the past five years, Receivables - Notes ranged from a high of $832454.0 in Q2 2012 to a low of $163829.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Rezolute | 31,153.77 | 31,153.77 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 163,829.00 |
| Jun 30, 2012 | 832,454.00 |